Protocol for short-term tumor development, as an option for the study of chemopreventive agents

Protocolo para el desarrollo de tumores a corto plazo, como opción para el estudio de agentes quimiopreventivos

María S. Cid-Gallegos 1 © 0000-0001-9523-4376
Xariss M. Sánchez-Chino 2 © 0000-0002-8599-8150
Isela Álvarez-González 3 © 0000-0003-4011-9121
Eduardo Madrigal-Bujaidar 3 © 0000-0003-4256-1749
Verónica R. Vásquez-Garzón 4 © 0000-0002-4861-8235
Rafael Baltiérrez-Hoyos 4 © 0000-0003-3416-6917
Cristian Jiménez-Martínez 1 © 0000-0001-8921-9858

1 Instituto Politécnico Nacional, Unidad Profesional Adolfo López Mateos, Zacatenco, Departamento de Ingeniería Bioquímica, Escuela Nacional de Ciencias Biológicas
2 Cátedra Conacyt, El Colegio de la Frontera Sur-Villahermosa, Departamento de Salud
3 Instituto Politécnico Nacional, Unidad Profesional Adolfo López Mateos, Zacatenco, Laboratorio de Genética, Escuela Nacional de Ciencias Biológicas
4 Cátedra Conacyt, Universidad Autónoma Benito Juárez de Oaxaca, Facultad de Medicina y Cirugía

Palabras clave: cáncer de colon; carcinogénesis; estadios; protocolos; supervivencia; modelos in vivo; ratones BALB/c; azoximetano; dextran sulfato de sodio; oxidación de lípidos; oxidación de proteínas; inflamación; tumores; compuestos; quimioprevención

Keywords: colon cancer; carcinogenesis; stadiums; protocols; survival; in vivo models; BALB/c mice; azoxymethane; sodium dextran sulfate; lipid oxidation; protein oxidation; inflammation; tumors; compounds; chemoprevention

Resumen

Introducción: El diagnóstico del cáncer de colon suele realizarse de forma tardía, por lo que suelen buscarse varias opciones para su prevención. Para esto, los modelos in vivo resultan una opción para la evaluación de agentes quimiopreventivos. Estos modelos se basan principalmente en la inducción y promoción de la carcinogénesis; sin embargo, tardan mucho tiempo. Este trabajo tuvo como objetivo evaluar y proponer un modelo de carcinogénesis con manifestación tumoral en menos tiempo, para comprobar la eficacia de compuestos quimiopreventivos.

Método: Se indujo carcinogénesis de colon en tres grupos (n = 7) de ratones macho BALB/c con azoximetano (AOM) y dextran sulfato de sodio (DSS). El daño se evaluó 14 semanas después de la inducción. Los protocolos fueron los siguientes: 1) P1: dos inyecciones de AOM y dos ciclos de
Protocol for short-term tumor development, as an option for the study of chemopreventive agents

DSS al 1.5 % durante cinco días, con tres días de descanso entre ciclos; 2) P2: una inyección de AOM y dos ciclos de DSS al 2 % durante siete días, con cinco días de descanso, y 3) P3: una inyección de AOM y dos ciclos de DSS al 2 % durante cuatro días, con cuatro días de reposo. Se utilizó control negativo en paralelo, P0: con una inyección de solución salina y agua ad libitum. Se determinó peso, índice de actividad de la enfermedad (DAI), supervivencia, incidencia de tumores, lípidos y oxidación de proteínas.

Resultados: P2 mostró mayor severidad en los signos evaluados (100 % de incidencia de tumores, peso/longitud de colon 101.68 ± 2.99 mg/cm), con baja supervivencia (43 %); P1 presentó menor mortalidad (14 %) y 83 % de incidencia de tumores, sin diferencia significativa con P2. P3 desarrolló la enfermedad, pero en menor grado (33 % incidencia de tumores). Además, los tres protocolos mostraron oxidación de lípidos (0.4-0.58 ng/μg de proteína) y proteínas (0.6-1 ng/μg de proteína). Los protocolos de inducción P1 y P3 presentaron menor mortalidad, pérdida de peso y DAI aceptable, relación peso/longitud de colon superior al control negativo y presencia de tumores.

Discusión o Conclusión: El uso de AOM (10mg/kg) combinado con DSS (1.5-2 %) son modelos adecuados para evaluar el efecto carcinogénico de compuestos de interés, signos de inflamación, oxidación de lípidos y proteínas, y un número de supervivencia necesario para realizar el análisis estadístico que conduzca a conclusiones certeras. Por tanto, P1 y P3 son protocolos que pueden utilizarse con resultados satisfactorios para los ensayos de quimioprevención.

Abstract

Introduction: Colon cancer diagnosis is usually performed late; so, it is necessary to search for prevention options. In vivo models are an option for the evaluation of chemopreventive agents, which are based mainly on the induction and promotion of carcinogenesis; however, they take a long time. This work aimed to evaluate and propose a carcinogenesis model, with tumor manifestation in a short time to prove the efficacy of chemopreventive compounds.

Method: Colon carcinogenesis was induced in three groups (n = 7) male BALB/c mice with azoxymethane (AOM) and dextran sodium sulfate (DSS). The damage was assessed 14 weeks after the induction. Protocols were: 1) P1: two AOM injections and two DSS cycles at 1.5 % for five days, with three resting days between cycles; 2) P2: one AOM injection and two DSS cycles at 2 % for seven days with five rest days, and 3) P3: one AOM injection and two DSS cycles at 2 % for four days, with four resting days. Negative control was used in parallel, P0: with one injection of
saline solution and water *ad libitum*. Weight, disease activity index (DAI), survival, tumor incidence, lipids, and protein oxidation were determined.

**Results:** P2 showed greater severity in the assessed signs (100 % tumor incidence, colon weight/length ratio 101.68 ± 2.99 mg/cm), with low survival (43 %). P1 depicted lower mortality (14 %) and 83 % tumor incidence, without a significant difference to P2. P3 developed the disease but to a lesser degree (33 % tumor incidence). Furthermore, the three protocols showed lipid oxidation (0.4-0.58 ng/μg of protein) and proteins oxidation (0.6-1 ng/μg of protein). The P1 and P3 induction protocols presented less mortality, weight loss, and acceptable DAI, a weight/length ratio higher than the negative control and presence of tumors.

**Discussion or Conclusion:** The use of AOM (10mg/kg) combined with DSS (1.5-2 %) are suitable models to evaluate the carcinogenic effect of compounds of interest, inflammation signs, lipids and proteins oxidation and a survival number adequate to perform the statistical analysis leading to accurate conclusions. Therefore, P1 and P3 are protocols that can be used in chemoprevention assays with satisfactory results.

---

**Introduction**

Colon cancer (CC) is a severe public health problem that occupies the 3rd place in incidence, and is the second type of cancer with the highest mortality worldwide (Bray et al., 2018). Approximately only 10 % of the reported cases are the familial types, whereas 90 % are of the sporadic type, related to the lifestyle, i.e., a diet low in fiber, high in saturated fats and simple sugars, as well as alcohol abuse, sedentary, and intestinal dysbiosis, among others (Sakita et al., 2017).

Carcinogenesis is a multistage process that starts when a normal cell undergoes mutation, without being able to be healed naturally, accumulating several injuries in diverse biological levels, including genetic and biochemical changes among cells that divide until a carcinoma appears (Rowles & Erdman, 2020).

The CC diagnosis is usually delayed, and its treatment is costly for the patient and the medical services of each country (Orangio, 2018). There are several treatments for CC, such as: surgical, radiotherapy, chemotherapy, directed therapy, immunotherapy, and alternative therapies (Mishra et al., 2013), which have shown efficacy depending on the cancer staging and the general
conditions of patients. Chemotherapy, radiotherapy, targeted therapy, and immunotherapy are usually treatments in which agents, like 5-fluorouracil, oxaliplatin, irinotecan, capecitabine, bevacizumab, cetuximab, PD-1 inhibitors, among others, are used. These agents can be aggressive because they induce side effects like diarrhea, nausea, hair loss, tiredness, neutropenia, cardiotoxicity, nephrotoxicity, hepatotoxicity, among others (Dienstmann et al., 2015; Hammond et al., 2016; Wu, 2018).

Moreover, the objective of any cancer therapy is its complete eradication, without damaging the rest of the organism. Among the factors to consider in choosing a therapy are the patient’s condition, the location, the stage, and the type of cancer. The notion that most cancers are preceded by premalignant lesions and that their extirpation or suppression is useful to cease the process has hindered the development of the preventing approach and that nutrition is a fundamental part of it (Ricciardiello et al., 2016). Therefore, chemoprevention of cancer is an alternative consisting of the use of non-toxic natural or chemical compounds to prevent, delay, or inhibit carcinogenesis in healthy people or in the early stages (Chhabra et al., 2018). In the diet, diverse compounds can be found in fruits, vegetables, cereals, or legumes, like phenolic and nitrogenated compounds, organosulfur compounds, carotenoids, phytosterols, essential oils, polyunsaturated fatty acids, and fibers, with chemopreventive characteristics, especially for the colon, as they involve diverse action mechanisms, including antioxidant, anti-inflammatory, antimutagenic, inhibitors of uncontrolled cell proliferation, migrations, angiogenesis, apoptosis, and interaction with the intestinal microbiota, among others (Costea et al., 2018). A desirable characteristic for chemopreventive compounds is that they are accessible (available and of low cost). Hence, evaluation of foods is an opportunity to identify and promote the consumption of those with the above-mentioned qualities.

To study the CC experimentally in animals, two compounds have been mainly used: azoxymethane (AOM) and the promotor dextran sodium sulfate (DSS) (Chassaing et al., 2014; Venning et al., 2013). DSS has the advantage that it can be administered in drinking water to rodents in one or more cycles to promote a sustained inflammatory stage, exerting a toxic effect on the colon epithelium (Thaker et al., 2012), whereas AOM is a genotoxic agent that starts carcinogenesis by alkylating the DNA bases, fostering mismatches in them (Neufert et al., 2007). Among the disadvantages of this model is that they require a long period for the development of tumors, which, in general, takes between 20 and 30 weeks (Neufert et al., 2007; Tanaka et al., 2003). Therefore, in this work, the number of AOM administrations (1-2) and the used doses (10-15 mg/kg), as well
as the DSS concentration (1-2.5 %), the cycles (1-4), and the duration of the cycles (4-7 days) have been modified, in addition to changing the strain of the experimental animals (Cuéllar-Núñez et al., 2018; Elimrani et al., 2017; Ju et al., 2016; Sánchez-Chino et al., 2017). Suzuki et al. (2006) reported that the BALB/c strains depicted a 100 % incidence of adenocarcinomas at the end of 18 experimental weeks.

The objective of this research was to obtain a protocol that, in the least time, will allow the development of tumors for the assessment of chemopreventive agents.

**Methods**

**Animals**

The animals used for the experimental protocol were BALB/c male mice (from the animal facilities of the FES Iztacala of the Universidad Nacional Autónoma de México, Tlalnepantla, Estado de México, México) with the following characteristics: 6-8 weeks of age and weight in the range of 20-25 g. The conditioning period for all mice was seven days with 12 h light/darkness cycles at 23 °C, free of pathogens. During this period, they were supplied with standard laboratory animal feed (Rodent Laboratory Chow 5001; LabDiet, USA) and purified water, both *ad libitum*. All animal studies were conducted with the ethical approval of the ethics committee of Escuela Nacional de Ciencias Biológicas/Instituto Politécnico Nacional (ENCB/IPN) approved the experimental protocol carried out in this research (Approval No. CEI-ENCB-011-2017) on June 14, 2017, and in accordance with the internationally accepted principles for laboratory animal use and care (NOM-062-ZOO-1999, 1999).

**Induction of colon cancer**

Colon cancer was induced with AOM (A5486, Sigma-Aldrich, USA) and DSS (36,000-50,000 M.W., CAS 9011-18-1, MP Biomedicals, CA) as promoter. After a 7-days adaptation period, animals were divided in four groups of seven mice each; three protocols were designed (figure 1) and one group corresponded to the control animals, based on reports by Tanaka *et al.* (2003), but making changes in the doses, concentrations, and times of administration of carcinogens according to the following scheme: P0 (control group), one intraperitoneal injection of saline solution and water *ad libitum*; P1: two intraperitoneal injections of 10 mg/kg of AOM, one each five days, and two cycles of 1.5 % DSS in the water *ad libitum* for five days, and three resting days between each
cycle; P2: one intraperitoneal injection of AOM (10 mg/kg), then five days passed and were administered two cycles of 2 % DSS in the water *ad libitum* during seven days for each cycle, and 5-day resting period between each cycle. Finally, P3: one intraperitoneal injection of AOM (10 mg/kg), then five days passed and continued with two DSS cycles at 2 % in the water provided *ad libitum* for four days for each cycle and four resting days between each cycle. Once carcinogenesis had been induced, animals were maintained in 12-h dark/light cycle at 23 °C with food and water for 14 weeks; at the end of the experimental period, animals were euthanized by cervical dislocation.

**Figure 1. Experimental protocols.**

**Figura 1. Protocolos experimentales.**

**General observations**

The weight and disease activity index (DAI) of each animal were monitored weekly. The DAI was calculated as follows: 0 = normal, 1 = soft stools without visible blood (diarrhea), 2 = visible blood in stools, 3 = soft stools with blood (Shi *et al*., 2015). Besides, the survival of animals in each protocol was assessed along the 14 experimental weeks.
Macroscopic appearance and incidence of colon tumors
After euthanizing animals, the colon was excised, washed with Phosphate-buffered saline (PBS) pH 7.4, at 4 °C, and fixed with 4 % formaldehyde in PBS, pH 7.4, for 24 h in a Petri dish with solid paraffin in the bottom. The whole colon was weighed and measured for further analysis. The presence of tumors was observed macroscopically according to the definition of the National Cancer Institute of US (NCI, 2021, T): “abnormal mass of tissue that appears when cells multiply more than needed”. Incidence of tumors in whole colon was calculated for each group (Cuellar-Nuñez et al., 2018).

Quantification of oxidized proteins in colon homogenates
To quantify oxidized proteins, 0.35-0.4 g of whole colon were weighed and homogenized in an ULTRA-TURRAX® in PBS (1:10), pH 7.4, at 4° C for 30 s. For this test, 200 µL of the homogenate was mixed with 500 µL of 2,4-Dinitrophenylhydrazine (DNFH, D199303, Sigma, USA), incubated for 1 h at room temperature in darkness and supplemented with 500 µL of Trichloroacetic acid (TCA, T6399, Sigma Aldrich, USA); to precipitate the hydrazones, this mixture was homogenized and centrifuged at 13,600 g for 10 min. The pellet was recovered and washed three times with 1 mL of an ethyl-ethanol (1:1) solution, the pellet was resuspended with 1 mL of guanidine hydrochloride (G4505, Sigma Aldrich, USA), incubated at 37 °C/15 min and centrifuged at 13,600 g for 10 min. The supernatant was read at 361 nm in a UV-VIS spectrophotometer (Thermo Spectronic, Genesys 20, CA, USA). The concentration of oxidized carbonyls (OC) was calculated with a molar extinction coefficient of 21,000 M and expressed as nanograms per microgram of protein (ng/µg protein) (Sánchez-Chino et al., 2017).

Quantification of oxidized lipids in colon homogenates
For this, 500 µL of the homogenized whole colon and 2 mL of TCA-TBA-HCl (15 % w/w – 0.375 w/v – 0.25N) were used. The mixture was boiled for 15 min, cooled in an ice bath for 10 min, centrifuged at 4,000 rpm for 10 min; the supernatant was recovered and read at 532 nm in a UV-VIS spectrophotometer (Thermo Spectronic, Genesys 20). The result was expressed in nanograms (ng) of malondialdehyde (MDA) per microgram (µg) of total protein with a molar extinction coefficient of 156,000 M (Sánchez-Chino et al., 2017).
Protocol for short-term tumor development, as an option for the study of chemopreventive agents

Statistical analyses
All results were processed through descriptive statistics, using mean central tendency measures ± standard error (SE). With the Minitab 17.0 statistical software, a one-way variance analysis (ANOVA) and a Tukey-Kramer comparison test were performed to identify significant differences among groups.

Results
General observations
The toxicity signs induced by the carcinogens are the weight loss, DAI, and survival, which were monitored during the 14 experimental weeks. Figure 2A shows that the three protocols, studied from induction and up to week 3, presented a lower weight gain with respect to P0. During DSS application, P2 presented a 2 g reduction compared to the initial weight. Starting with week 3, P1 maintained a constant weight until the end of the experiment, and this weight was kept below P0 along the whole experiment. Regarding P2, along the experiment, the weight depicted an irregular behavior perhaps due to the low survival percentage (43 %), however, at the end of the experiment, it showed the same weight as P1, in both cases, the weights were 10 % lower and statistically different (p < 0.05) from P0. Whereas P3, which during the first six weeks maintained its weight below the other used protocols, its weight gain was sustained and, starting at week 8, the weight was similar to that of P0, without significant difference (p < 0.05). Thus, the applied carcinogens will influence weight loss during induction and at the end of the experiment due to disease development.

The DAI indicates the toxic clinical effects caused by the administration of DSS. The stools were observed macroscopically revealing that P0 did not present any toxicity sign. During the induction period, P2 revealed a higher DAI than the other protocols, once the induction finished, a recovery period started. This parameter fluctuates irregularly along the experiment and, in week 10, an increase in the toxicity signs was observed anew. P1, during induction, showed an increase in DAI, during this period maximal damage was reached. Once the induction finished, a recovery period was observed that was lost at week 3, in which the damage increased, and from this period to the end of the experiment it increases constantly, reaching a similar damage to that shown during induction. P3, from induction until week 2, presented the highest damage, after this week a recovery started that was maintained until the end of the experiment; however, at week 6, there is
a peak that was related with the death of one of the experimental animals (figure 2B). All P0 animals (100 %) survived the whole experiment, whereas P1 and P3 had an 86 % survival each one (figure 2C). The protocol with the highest mortality was P2 with 57 %, due to the toxicity presented by the administered AOM/DSS doses, which discards this model as induction system.

**Figure 2. General observations on the colon carcinogenesis induction protocols.**
**Figura 2. Observaciones generales sobre los protocolos de inducción de carcinogénesis de colon.**

A) Weight, B) DAI, C) Percentage of survival during the 14 experimental weeks (n = 7). P1) Two AOM injections and two DSS cycles at 1.5 % for five days, with three resting days; P2) One AOM injection and two DSS cycles at 2 % for seven days with five resting days, and P3) One AOM injection and two DSS cycles at 2 % for four days, with three resting days. Different letters in the groups represent significant differences among them. Unifactorial ANOVA (p < 0.05), Tukey-Kramer’s test.
Protocol for short-term tumor development, as an option for the study of chemopreventive agents

Nota: A) Peso, B) Disease Activity Index (DAI), C) Porcentaje de supervivencia durante las 14 semanas experimentales (n = 7). P1) Dos inyecciones de AOM y dos ciclos de DSS al 1.5 % durante cinco días, con tres días de reposo; P2) Una inyección de AOM y dos ciclos de DSS al 2 % durante siete días con cinco días de reposo, y P3) Una inyección de AOM y dos Ciclos de DSS al 2 % durante cuatro días, con tres días de reposo. Las letras diferentes en los grupos representan diferencias significativas entre ellos. ANOVA unifactorial (p < 0.05), prueba de Tukey-Kramer.

**Weight/length (mg/cm) ratio and incidence of colon tumors**

At the end of the 14 experimental weeks, animals were euthanized, the tissue was extracted and processed as described in the Methods section. The weight/length ratio was assessed as one of the colon inflammations signs of the experimental animals. In the P0, the observed relation was lower than that observed in the other protocols: P1 was significantly different (p < 0.05) from P0, but presented less damage than P2 and P3, the three protocols were significantly different among them (p < 0.05); in P2, the damage was larger than in the other protocols. In P3, a 47 % increase in the weight/length ratio was observed with respect to P0 (table 1).

| Group | Weight/length (mg/cm) ratio | Incidence of tumors (%) |
|-------|-----------------------------|-------------------------|
| P0    | 43.92 ± 1.31a               | 0                       |
| P1    | 58.11 ± 1.00b               | 83*                     |
| *P2   | 101.68 ± 2.99d              | 100                    |
| P3    | 62.92 ± 1.26c               | 33                     |

Note: Results present the mean ± SE (p < 0.05) (n = 5 and *P2 n = 3). Different letters in the columns indicate significant differences among groups. Unifactorial ANOVA (p < 0.05), Tukey test. Incidence represents number of mice with tumors per group.

Nota: Los resultados representan la media ±EE (p < 0.05) (n = 5 y *P2 n = 3). Diferentes letras en las columnas indican diferencia significativa entre grupos. Unifactorial ANOVA (p < 0.05), Prueba de Tukey. La incidencia representa el número de ratones con tumores por grupo.

In the control group (P0), none of the animals presented tumors; of the tested protocols, the one with the lowest response was P3, because only 33 % of the animals presented tumors. In P1, the incidence was of 83 %, whereas 100 % of the survived animals of P2 presented tumors. The three protocols presented a significant difference (p > 0.05).
Lipids and proteins oxidation
Assessment of oxidation markers is shown in figure 3. P0 shows the basal concentration of MDA and OC, which were 0.298 and 0.418 ng/µg protein, respectively. The highest oxidation was observed in P2, for both lipids and proteins, being 1.9- and 2.2-times higher for each one with respect to P0. P1 presented 0.507 and 0.650 ng/µg protein, for MDA and OC, respectively. P3 was the one with the least damage, with only 1.5- and 1.4-times the MDA and OC concentrations as compared to P0, revealing a significant difference among the assessed protocols (p > 0.05). Proteins were the most oxidized molecules.

Figure 3. Quantification of lipid and protein oxidation products during colon carcinogenesis (n = 3).

Proteins by being abundant in biological systems are more susceptible to oxidative stress; in this way, carbonyl groups were assessed to measure the oxidation of proteins (Davies, 2016). Results
of OC quantification revealed that P1 and P3 presented a higher concentration of OC, being statistically significant (p < 0.05) compared to P0 (figure 3).

**Discussion**

One of the main issues when attempting to study chemopreventive agents found in foods is that the models usually take a long time to develop tumors (An et al., 2014; Shi et al., 2015; Elimrani et al., 2017; Sánchez-Chino et al., 2017; Cheng et al., 2018). Besides, it is also ideal to assess in different stages, both early and late, to determine the efficacy of the chemopreventive agent. Given that the sporadic colon cancer is caused mainly by the chronic exposure to small amounts of mutagens/carcinogens and promotors present in the environment, models have been proposed that used genotoxic and inflammatory agents. Among the most used are those in which an inducer is combined with a promoter (Tanaka et al., 2003).

In this research, a protocol was obtained that in a lesser time allowed for the development of tumors to assess natural products as chemopreventive agents. The combination of AOM administered at 10 mg/kg of weight (1-2 doses) and DSS at 1.5-2 % (4-7 days) in the drinking water allowed observing tumors in 14 weeks in the experimental animals (male BALB/c mice). Ju et al. (2016) and Lin et al. (2020) developed models that in a short time gave rise to tumors, but using genetically modified animals, which does not provide an actual knowledge of the environment or of the environmental factors that influence the sporadic cancer and, besides, they increase the research cost.

One of the observed clinical signs, during the development of the protocols, was the weight loss. Byun et al. (2015) observed this same effect and reported weight loss in groups treated with AOM/DSS one week after the administration of DSS (2 and 1 %), with a weight recovery between each cycle of DSS administration (five days), this may be due because the resting period applied was of 15 days among them. In another study, Elimrani et al. (2017) reported a 5 to 20 % weight loss in all mice treated with AOM/DSS; in the present study, the highest weight loss of experimental animals was observed during induction, showing a recovery period in weeks 3 to 10 of the experiment.

In cancer patients, there is, generally, weight loss, which has been attributed normally to the diminution of skeletal muscle as a response to the overactivation of proteolysis together with the reduction in proteins synthesis (Tan & Fearon, 2008). This phenomenon is known as cachexia.
due to cancer, a term that refers to a multifactorial syndrome characterized by a loss of skeletal muscle mass (with or without fatty mass), which cannot be reversed completely with the conventional nutritional support and leads to a progressive functional deterioration. Its physiopathology is characterized by a negative balance of proteins and energy, triggered by a variable combination of reduced food consumption and abnormal metabolism. The diagnostic criterion for cachexia is a weight loss over 5 %, which is also associated with a reduction in life quality and duration. In oncological patients, a mortality of 20 to 30 % has been estimated due to this syndrome (Bonetto et al., 2016; Fearon et al., 2011). Bonetto et al. (2016) reported that CD2F1 adult mice carriers of the C26 carcinoma lost body weight, which they associated with wear off the skeletal muscle and reduction in the muscular fiber size, demonstrated through morphometric assessment. Besides, this was associated with the presence of proinflammatory molecules, especially interleukin 6 (IL-6), as well as with the activation of proteolysis.

DSS is used in a model to study intestinal inflammatory diseases, because it is 100 % reproducible, as it produces chronic colitis, which is manifested by diarrhea, bleeding, prolapse, weight loss, shortening of the colon, ulceration of the mucosa, and neutrophilic infiltration (Sasaki et al., 2003). Chronic DSS ingestion is associated with epithelial dysplasia that progresses to an invasive adenocarcinoma (Sasaki et al., 2003; Elson et al., 1995). In this study, the toxicity signs were manifested from the first days of DSS administration, diminishing during the resting periods and up to week 4 after induction. Jeon et al. (2018) showed similar results, mentioning that the DAI increased daily during the first week of DSS treatment and diminished in the resting periods. Elimrani et al. (2017) reported the appearance of toxic clinical signs related to colitis starting on the 3rd day of DSS administration, which increases the severity of colitis, inducing a progressive weight loss, bleeding, and diarrhea. Shi et al. (2015) observed bleeding and soft stools one week after administering DSS, and the signs increased five days after induction with AOM/DSS. Notably, DAI is a recognized marker to measure chronic inflammation in colon since it combines various signs such as: weight loss, diarrhea, blood stool, and it has been better predictor of colon carcinogenesis, providing the degree of severity of the inflammatory process that it can be correlated with damage to intestinal mucosa that the expression of some molecular markers such as interleukin 1β (IL-1β) is an inflammatory cytokine produced predominantly by macrophages and activated monocytes or histological damage to tissues (Oliveira et al., 2014; Park et al., 2015). Moreover, Park et al. (2015) reported in their DSS induction model that mice treated with different
doses and exposure times the best marker was DAI. That is why this type of marker was used as an approach to evaluate chemopreventive agents in this trial.

Mortality is another clinical sign of CC, however, it is important to count upon a representative sample, hence, it is advisable to have at least six animals per experimental group (n = 6) at the end of the experiment to detect statistical differences (Bonetto et al., 2016). Jeon et al. (2018) reported that the increase of the toxicity signs like weight loss, diarrhea, and bleeding, which reflect an increase of the DAI, led to mortality among AOM/DSS-treated animals. P2 of this study had an increased DAI during induction and an irregular behavior along the experiment, with fluctuations in toxicity signs, which induced a higher mortality among the animals of this protocol; hence, although signs developed successfully, this protocol was discarded due to its effect on mortality. Elimrani et al. (2017) reported that in the positive control with AOM/DSS less than 50 % of animals survived; therefore, analyses were performed only in three of the ten animals, which, according to Bonetto et al. (2016) would not represent a convenient statistical analysis. Groups P1 and P3 complied with an adequate number of live animals (n = 6) at the end of the experiment to perform an adequate statistical analysis with three animals for each determination, hence, they are to be considered appropriate protocols for assays with foods, according to the pursued objective.

The weight/length ratio of the colon is used as a marker of hyperplasia of the mucosa and of the severity of chronic colitis; because DSS induces a shortening of the colon, this can be used as a visual index and has been used for the study of foods with anti-inflammatory potential (Cuéllar-Núñez et al., 2018; Elimrani et al., 2017). Furthermore, a characteristic of intestinal inflammation is the thickening and shortening of the large bowel which can be measured in mice as an increase in the colon weight/length ratio, which is and indirect indicator of colonic edema and inflammation (Sydora et al., 2012; Daniluk et al., 2017).

Okayasu et al. (1990) proposed a model for the induction of chronic ulcerative colitis with DSS and found that the colon of DSS-treated animals was significantly shorter than in non-treated animals. Cuéllar-Núñez et al. (2018), in a carcinogenesis model of one AOM injection (10 mg/kg) and three cycles of DSS at 2 % in the drinking water, reported that the colon of these animals was 35 % shorter than in non-treated animals. Ju et al. (2016) observed that the weight/length ratio of the colon increases 4-times with the administration of AOM/DSS respect to a non-treated group.

Cuéllar-Núñez et al. (2018) reported a 100 % incidence of tumors in mice treated with AOM/DSS (DSS at 3 % in the drinking water). Zhang et al. (2018) observed 100 % of neoplasms
in C57BL/6 mice at the end of 63 experimental days with a model consisting of one injection of AOM (10 mg/kg) and three cycles of DSS at 1% in the drinking water with 15 resting days among cycles, whereas Shi et al. (2015) reported 100% of tumors in ICR mice at the end of 20 experimental weeks with one injection of AOM (10 mg/kg) and one cycle of DSS at 2% for seven days in the group with AOM/DSS. The DSS cycles differed in the three mentioned models in which 100% of tumors were obtained, because the concentration, time of exposure, and the mouse strain differed and indicate that modifications can be made regarding the DSS cycles to obtain positive results. In the assay performed here, mice were BALB/c strain and a 100% of tumors was obtained in the P2 group in which mortality was extremely high, but PI had 83% tumors and more than 50% of animals survived.

The development of carcinogenesis induces oxidative stress, which affects molecules like proteins that are found in a higher proportions and fatty acids are important targets of lipid peroxidation (Hawkins & Davies, 2019; Ramana et al., 2017).

Lipids oxidation is considered a relevant mechanism in the destruction of cell membranes, as well as for deteriorations of enzymes and receptors bound to those membranes (Betteridge, 2000). MDA is considered the main aldehyde from lipoperoxidation, hence, its determination through spectrophotometry by quantifying the adducts formed between the thiobarbituric acid (TBA) with alkenes, alkadienes; thus, MDA is considered a reliable marker of oxidative stress (Shichiri, 2014). Regarding proteins oxidation, the oxidized carbonyl groups are the product of this oxidative process in which the conformation, activity, and function of the proteins have been altered, so that they become resistant to proteolysis and affect the functionality of disease-challenged cells (Hecker & Wagner, 2018). Carbonyl groups are formed by the interaction of the amine group with the products of lipid peroxidation, like MDA and 4-hydroxy-2-nonenal (Stadtman, 2001).

The quantification of MDA and OC confirmed that the three protocols oxidized lipids and proteins significantly along the experiment. A higher proteins oxidation was obtained with the three protocols, similarly to the report by Sánchez-Chino et al. (2017). With this model, at the end of the experiment, it is also possible to assess the oxidation of these macromolecules.

Based on the above mentioned, this model could also be useful in the study of foods with antioxidant activity and to evaluate, in in vivo studies, the capacity of inhibiting the oxidation of key carcinogenesis biomolecules, as well as to assess the impact that foods can have on the tumor
Protocol for short-term tumor development, as an option for the study of chemopreventive agents

microenvironment, which is highly oxidant (Costea et al., 2018; Prasad et al., 2017). Blocking the free radicals allows inhibiting cancer progression, because the first manifestation of the disease starts with an oxidation and inflammation caused by an oxidant environment induced by AOM and the inflammatory state induced by the DSS.

**Conclusion**
The P1 and P3 induction protocols presented less mortality, weight loss, and acceptable DAI, a weight/length ratio higher than the negative control and presence of tumors, as well as oxidation of molecules like lipids and proteins as markers of oxidative stress present in the carcinogenic process. Hence, these protocols are considered adequate to be used for chemoprevention assays in male BALB/c mice.

It is a challenge to identify models that can attain tumors in a reasonable time and which are reproducible, therefore, the implementation of a CC induction protocol that will allow for the assessment of tumors in a relatively short time span, is a useful tool for the analysis of foods with a protecting effect, where prevention or reversion of the CC is possible. In addition, it is important to analyze the food to be able to observe the action mechanisms and the synergism presented by the compounds that grant their chemoprotective capacity.

**Acknowledgments**
This research was supported by Consejo Nacional de Ciencia y Tecnología (Conacyt, México) and Instituto Politécnico Nacional (IPN, México).

**References**
An, J., Li, X.-N., Zhao, B.-C., Wang, Q., Lan, Y., & Wu, Q. (2014). Chemo-preventive effect of Angelica sinensis’ supercritical extracts on AOM/DSS-induced mouse colorectal carcinoma associated with inflammation. Zongguo Zhong yao za zhi= Zhongguo Zhongyao Zazhi= China Journal of Chinese Materia Medica, 39(7), 1265-1269.
Betteridge, D. J. (2000). What is oxidative stress? Metabolism, 49(2, Supplement 1), 3-8. https://doi.org/10.1016/S0026-0495(00)80077-3
Bonetto, A., Rupert, J. E., Barreto, R., & Zimmers, T. A. (2016). The colon-26 carcinoma tumor-bearing mouse as a model for the study of cancer cachexia. *J Vis Exp*(117), e54893. https://doi.org/10.3791/54893

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA-Cancer J Clin*, 68(6), 394-424. https://doi.org/10.3322/caac.21492

Byun, S.-Y., Kim, D.-B., & Kim, E. (2015). Curcumin ameliorates the tumor-enhancing effects of a high-protein diet in an azoxymethane-induced mouse model of colon carcinogenesis. *Nutr Res*, 35(8), 726-735. https://doi.org/10.1016/j.nutres.2015.05.016

Chassaing, B., Aitken, J. D., Malleshappa, M., & Vijay-Kumar, M. (2014). Dextran sulfate sodium (DSS)-induced colitis in mice. *Curr Protoc Immunol*, 104(1), 15.25.11-15.25.14. https://doi.org/10.1002/0471142735.im1525s104

Cheng, K., Metry, M., Felton, J., Shang, A. C., Drachenberg, C. B., Xu, S., Zhan, M., Schumacher, J., Guo, G. L., & Polli, J. E. (2018). Diminished gallbladder filling increased fecal bile acids, and promotion of colon epithelial cell proliferation and neoplasia in fibroblast growth factor 15-deficient mice. *Oncotarget*, 9(39), 25572. https://doi.org/10.18632/oncotarget.25385

Chhabra, G., Singh, C. K., Ndiaye, M. A., Fedorowicz, S., Molot, A., & Ahmad, N. (2018). Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications. *Cancer Lett*, 422, 9-18. https://doi.org/10.1016/j.canlet.2018.02.

Costea, T., Hudiță, A., Ciolac, O.-A., Gălățeanu, B., Ginghină, O., Costache, M., Ganea, C., & Mocanu, M.-M. (2018). Chemoprevention of Colorectal Cancer by Dietary Compounds. *Int J Mol Sci*, 19(12), 3787. https://doi.org/10.3390/ijms19123787

Cuéllar-Núñez, M. L., Luzardo-Ocampo, I., Campos-Vega, R., Gallegos-Corona, M. A., González de Mejía, E., & Loarca-Piña, G. (2018). Physicochemical and nutraceutical properties of moringa (*Moringa oleifera*) leaves and their effects in an in vivo AOM/DSS-induced colorectal carcinogenesis model. *Food Res Int*, 105, 159-168. https://doi.org/10.1016/j.foodres.2017.11.004

Daniluk, J., Daniluk, U., Reszec, J., Rusak, M., Dabrowska, M., & Dabrowski, A. (2017). Protective effect of cigarette smoke on the course of dextran sulfate sodium-induced colitis
is accompanied by lymphocyte subpopulation changes in the blood and colon. *Int J Colorectal Dis*, 32(11), 1551-1559. https://doi.org/10.1007/s00384-017-2882-9

Davies, M. J. (2016). Protein oxidation and peroxidation. *Biochem J*, 473(7), 805-825. https://doi.org/10.1042/Bj20151227

Dienstmann, R., Salazar, R., & Tabernero, J. (2015). Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. *J Clin Oncol*, 33(16), 1787-1796. https://doi.org/10.1200/JCO.2014.60.0213

Elimrani, I., Koenekoop, J., Dionne, S., Marcil, V., Delvin, E., Levy, E., & Seidman, E. G. (2017). Vitamin D reduces colitis-and inflammation-associated colorectal cancer in mice independent of NOD2. *Nutr Cancer*, 69(2), 276-288. https://doi.org/10.1080/01635581.2017.1263346

Elson, C. O., Sartor, R. B., Tennyson, G. S., & Riddell, R. H. (1995). Experimental models of inflammatory bowel disease. *Gastroenterology*, 109(4), 1344-1367. https://doi.org/10.1016/0016-5085(95)90599-5

Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., Davis, M., Muscaritoli, M., Ottery, F., Radbruch, L., Ravasco, P., Walsh, D., Wilcock, A., Kaasa, S., & Baracos, V. E. (2011). Definition and classification of cancer cachexia: an international consensus. *The Lancet Oncology*, 12(5), 489-495. https://doi.org/10.1016/S1470-2045(10)70218-7

Hammond, W. A., Swaika, A., & Mody, K. (2016). Pharmacologic resistance in colorectal cancer: a review. *Ther Adv Med Oncol*, 8(1), 57-84. https://doi.org/10.1177/1758834015614530

Hawkins, C. L., & Davies, M. J. (2019). Detection, identification, and quantification of oxidative protein modifications. *J Biol Chem*, 294(51), 19683-19708. https://doi.org/10.1074/jbc.REV119.006217

Hecker, M., & Wagner, A. H. (2018). Role of protein carbonylation in diabetes. *J Inherit Metab Dis*, 41(1), 29-38. https://doi.org/10.1007/s10545-017-0104-9

Jeon, H.-J., Yeom, Y., Kim, Y.-S., Kim, E., Shin, J.-H., Seok, P. R., Woo, M. J., & Kim, Y. (2018). Effect of vitamin C on azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated early colon cancer in mice. *Nutr Res Pract*, 12(2), 101-109. https://doi.org/10.4162/nrp.2018.12.2.101
Ju, J., Lee, G.-Y., Kim, Y.-S., Chang, H. K., Do, M.-S., & Park, K.-Y. (2016). Bamboo salt suppresses colon carcinogenesis in C57BL/6 mice with chemically induced colitis. *J Med Food, 19*(11), 1015-1022. https://doi.org/10.1089/jmf.2016.3798

Lin, R., Piao, M., Song, Y., & Liu, C. (2020). Quercetin Suppresses AOM/DSS-Induced Colon Carcinogenesis through Its Anti-Inflammation Effects in Mice. *J Immunol Res, 2020*. https://doi.org/10.1155/2020/9242601

Mishra, J., Drummond, J., Quazi, S. H., Karanki, S. S., Shaw, J. J., Chen, B., & Kumar, N. (2013). Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. *Crit Rev Oncol Hemat, 86*(3), 232-250. https://doi.org/10.1016/j.critrevonc.2012.09.014

Neufert, C., Becker, C., & Neurath, M. F. (2007). An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. *Nat Protoc, 2*(8), 1998. https://doi.org/10.1038/nprot.2007.279

NCI, N. C. I. (2021). *NCI dictionaries: tumor definition*. NIH, (National Institutes of Health). Retrieved March 26 from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tumor

NOM-062-ZOO-1999. (1999). *Norma Oficial Mexicana 062-ZOO-1999: Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio*. SAGARPA, (Secretaría de Agricultura, Ganadería, Desarrollo rural, Pesca y Alimentación). Retrieved March 26, 2021 from: https://www.gob.mx/cms/uploads/attachment/file/203498/NOM-062-ZOO-1999_220801.pdf

Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y., & Nakaya, R. (1990). A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. *Gastroenterology, 98*(3), 694-702. https://doi.org/10.1016/0016-5085(90)90290-H

Oliveira, L. G., Cunha, A. L., Duarte, A. C., Castaño, M. C., Chebli, J. M., & Aguiar, J. A. (2014). Positive correlation between disease activity index and matrix metalloproteinases activity in a rat model of colitis. *Arq Gastroenterol, 51*(2), 107-112. https://doi.org/10.1590/s0004-28032014000200007

Orangio, G. R. (2018). The economics of colon cancer. *Surg Oncol Clin N Am, 27*(2), 327-347. https://doi.org/10.1016/j.soc.2017.11.007
Park, Y. H., Kim, N., Shim, Y. K., Choi, Y. J., Nam, R. H., Choi, Y. J., Ham, M. H., Suh, J. H., Lee, S. M., Lee, C. M., Yoon, H., Lee, H. S., & Lee, D. H. (2015). Adequate Dextran Sodium Sulfate-induced Colitis Model in Mice and Effective Outcome Measurement Method. *J Cancer Prev*, 20(4), 260-267. https://doi.org/10.15430/JCP.2015.20.4.260

Prasad, S., Gupta, S. C., & Tyagi, A. K. (2017). Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals. *Cancer Lett*, 387, 95-105. https://doi.org/10.1016/j.canlet.2016.03.042

Ramana, K. V., Srivastava, S., & Singhal, S. S. (2017). Lipid Peroxidation Products in Human Health and Disease 2016. *Oxid Med Cell Longev*, 2017, 2163285-2163285. https://doi.org/10.1155/2017/2163285

Ricciardiello, L., Ahnen, D. J., & Lynch, P. M. (2016). Chemoprevention of hereditary colon cancers: time for new strategies. *Nat Rev Gastroenterol Hepatol*, 13(6), 352. https://doi.org/10.1038/nrgastro.2016.56

Rowles, J. L., & Erdman, J. W. (2020). Carotenoids and their role in cancer prevention. *Biochim Biophys Acta*, 158613. https://doi.org/10.1016/j.bbalip.2020.158613

Sakita, J. Y., Gasparotto, B., García, S. B., Uyemura, S. A., & Kannen, V. (2017). A critical discussion on diet, genomic mutations, and repair mechanisms in colon carcinogenesis. *Toxicol Lett*, 265, 106-116. doi: 10.1016/j.toxlet.2016.11.020.

Sánchez-Chino, X. M., Jiménez-Martínez, C., Vásquez-Garzón, V. R., Álvarez-González, I., Villa-Treviño, S., Madrigal-Bujaidar, E., Dávila-Ortiz, G., & Baltiérrez-Hoyos, R. (2017). Cooked chickpea consumption inhibits colon carcinogenesis in mice induced with azoxymethane and dextran sulfate sodium. *J Am Coll Nutr*, 36(5), 391-398. https://doi.org/10.1080/07315724.2017.1297744

Sasaki, M., Bharwani, S., Jordan, P., Eldred, J. W., Grisham, M. B., Jackson, T. H., Lefer, D. J., & Alexander, J. S. (2003). Increased disease activity in eNOS-deficient mice in experimental colitis. *Free Radical Bio Med*, 35(12), 1679-1687. https://doi.org/10.1016/j.toxlet.2016.11.020

Shi, N., Clinton, S. K., Liu, Z., Wang, Y., Riedl, K. M., Schwartz, S. J., Zhang, X., Pan, Z., & Chen, T. (2015). Strawberry Phytochemicals Inhibit Azoxymethane/Dextran Sodium Sulfate-Induced Colorectal Carcinogenesis in Crj: CD-1 Mice. *Nutrients*, 7(3), 1696-1715. https://doi.org/10.3390/nu7031696
Shichiri, M. (2014). The role of lipid peroxidation in neurological disorders. *J Clin Biochem Nutr*, 14-10.

Stadtman, E. R. (2001). Protein oxidation in aging and age-related diseases. *Annals of the New York Academy of Sciences*, 928(1), 22-38. [https://doi.org/10.1111/j.1749-6632.2001.tb05632.x](https://doi.org/10.1111/j.1749-6632.2001.tb05632.x)

Suzuki, R., Kohno, H., Sugie, S., Nakagama, H., & Tanaka, T. (2006). Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. *Carcinogenesis*, 27(1), 162-169. [https://doi.org/10.1093/carcin/bgi205](https://doi.org/10.1093/carcin/bgi205)

Sydora, B. C., Albert, E. J., Foshaug, R. R., Doyle, J. S., Churchill, T. A., & Fedorak, R. N. (2012). Intravenous injection of endogenous microbial components abrogates DSS-induced colitis. *Dig Dis Sci*, 57(2), 345-354. [https://doi.org/10.1007/s10620-011-1878-5](https://doi.org/10.1007/s10620-011-1878-5)

Tan, B. H. L., & Fearon, K. C. H. (2008). Cachexia: prevalence and impact in medicine. *Curr Opin Clin Nutr Metab Care*, 11(4), 400-407. [https://doi.org/10.1097/MCO.0b013e328300ecc1](https://doi.org/10.1097/MCO.0b013e328300ecc1)

Tanaka, T., Kohno, H., Suzuki, R., Yamada, Y., Sugie, S., & Mori, H. (2003). A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. *Cancer science*, 94(11), 965-973. [https://doi.org/10.1111/j.1349-7006.2003.tb01386.x](https://doi.org/10.1111/j.1349-7006.2003.tb01386.x)

Thaker, A. I., Shaker, A., Rao, M. S., & Ciorba, M. A. (2012). Modeling colitis-associated cancer with azoxymethane (AOM) and dextran sulfate sodium (DSS). *JoVE (Journal of Visualized Experiments)* (67), e4100. [https://doi.org/10.3791/4100](https://doi.org/10.3791/4100)

Venning, F. A., Claesson, M. H., & Kissow, H. (2013). The carcinogenic agent azoxymethane (AOM) enhances early inflammation-induced colon crypt pathology. *J Cancer Sci Ther*, 5(11), 377-383. [https://doi.org/10.1978-5956.1000229](https://doi.org/10.1978-5956.1000229)

Wu, C. (2018). Systemic therapy for colon cancer. *Surg Oncol Clin N Am*, 27(2), 235-242. [https://doi.org/10.1016/j.soc.2017.11.001](https://doi.org/10.1016/j.soc.2017.11.001)

Zhang, Y.-S., Wang, F., Cui, S.-X., & Qu, X.-J. (2018). Natural dietary compound naringin prevents azoxymethane/dextran sodium sulfate-induced chronic colorectal inflammation and carcinogenesis in mice. *Cancer Biol Ther*, 19(8), 735-744. [https://doi.org/10.1080/15384047.2018.1453971](https://doi.org/10.1080/15384047.2018.1453971)